NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, DNA repair, and sirtuin activation. Levels decline approximately 50% between ages 40 and 60. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors that the body converts to NAD+.
| Compound | Human Trials | Bioavailability | Key Researcher |
|---|---|---|---|
| NAD+ IV/IM | Limited | 100% (IV) | Various longevity clinics |
| NMN oral | Several Phase 1/2 | ~40% | Sinclair, Imai |
| NR oral | Most (Chromadex funded) | ~30–40% | Brenner |
Injectable NAD+ achieves maximum plasma elevation but requires sterile administration protocol. Oral NMN has the most recent positive human data, including a 2023 trial showing improved muscle function in older adults. NR has the longest human safety record but shows more variable NAD+ elevation between individuals.
Injectable NAD+ and oral NMN/NR capsules available at QSC Peptides.
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.